Roger J. Brideau
Research Subjects
Roger J. Brideau has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Audris Huang
Infectious Diseases Research, Pharmacia Corporation, Kalamazoo, Michigan
2 shared publicationsMary L. Knechtel
Infectious Diseases Research, Pharmacia Corporation, Kalamazoo, Michigan 49001, USA
2 shared publicationsValerie A. Vaillancourt
Infectious Diseases Research, Pharmacia Corporation, Kalamazoo, Michigan
2 shared publicationsBob D. Rush
1 shared publicationEllen E. Vera
1 shared publicationFrancis J. Schwende
1 shared publication
Latest Publications
- 12 August 2002
- Published by Wiley in Journal of Medical Virology
- Vol. 68 (2) , 234-236
Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU‐183792, a 4‐oxo‐dihydroquinoline
The susceptibility of human cytomegalovirus (CMV) and varicella zoster virus (VZV) clinical isolates to PNU‐183792, a 4‐oxo‐dihydroquinoline, was examined. The antiviral potency of PNU‐183792, a non‐nucleoside inhibitor, was compared to the licensed nucleoside inhibitors ganciclovir and acyclovir using plaque reduction and virus yield reduction assays. PNU‐183792 was as potent against CMV as ganciclovir and was superior in potency to acyclovir against VZV. PNU‐183792 represents a new class of non‐nucleoside inhibitors of human herpesviruses. J. Med. Virol. 68: 234–236, 2002.
- 12 August 2002
- Published by Wiley in Journal of Medical Virology
- Vol. 68 (2) , 234-236
Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU‐183792, a 4‐oxo‐dihydroquinoline
The susceptibility of human cytomegalovirus (CMV) and varicella zoster virus (VZV) clinical isolates to PNU‐183792, a 4‐oxo‐dihydroquinoline, was examined. The antiviral potency of PNU‐183792, a non‐nucleoside inhibitor, was compared to the licensed nucleoside inhibitors ganciclovir and acyclovir using plaque reduction and virus yield reduction assays. PNU‐183792 was as potent against CMV as ganciclovir and was superior in potency to acyclovir against VZV. PNU‐183792 represents a new class of non‐nucleoside inhibitors of human herpesviruses. J. Med. Virol. 68: 234–236, 2002.
- 1 April 2002
- Published by Elsevier in Antiviral Research
- Vol. 54 (1) , 19-28
Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses
- 1 April 2002
- Published by Elsevier in Antiviral Research
- Vol. 54 (1) , 19-28
Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses